Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Don Haut joined AskBio in March 2020 & acquired October 2020
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jan 07, 2021 10:54am
178 Views
Post# 32241784

RE:Don Haut joined AskBio in March 2020 & acquired October 2020

RE:Don Haut joined AskBio in March 2020 & acquired October 2020
themagicbox wrote: Its interesting that he joined AskBio in March 2020 as Chief Business Officer to lead its business development strategy and execution.

AskBio was aquired by Bayer for $4billion, which was annoucned in October 2020 i.e. 7 months later.

While you cant make a direct comparison with accuracy, directionally however, if we were to apply that timeline to ATE, we might get a deal in August.


If we get a buyout deal, guessing it happens within 12 months since Phase 2B results.  That takes us to summer of 2021.  Right in line with what you are saying.

I would still assume we are getting a better financial deal by partnering with 3-4 pharmas for OTENA ... unless ... one or two Big Pharmas step up and get serious.  Just my opinion.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities